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Sirtuins are highly conserved NAD+-dependent enzymes that were shown to have
beneficial effects against age-related diseases. Alzheimer’s Disease (AD) is the most
common neurodegenerative disorder associated with aging and the effects of sirtuins on
AD have been investigated using different mouse and cell culture models. In most of these
studies, it has been found that the overexpression of SIRT1 has protective effects against
the AD phenotype. Therefore, designing therapeutics based on SIRT1 activity might be
important to investigate treatment methods for this disease. In this review, we summarize
the recent research regarding the functions of sirtuins and their potential roles in designing
therapeutics for AD.
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INTRODUCTION
Sirtuins are conserved NAD+-dependent enzymes that display
beneficial effects in age-related disorders. They are also stress-
response proteins that help mammals adapt to dietary manip-
ulations (Donmez and Guarente, 2010). Various substrates have
been discovered for sirtuins, especially for SIRT1, the most widely
studied sirtuin in the brain (Haigis and Sinclair, 2010). SIRT1
has been analysed in many common neurodegenerative disor-
ders such as Alzheimer’s, Parkinson’s, and Huntington’s Diseases,
among others (Donmez, 2012). In this review, we will focus on the
findings regarding the functions of sirtuins and their implications
in Alzheimer’s Disease (AD).
SIRTUIN BIOLOGY
Sirtuins were first identified in yeast, named as silent informa-
tion regulators (SIRs) and grouped as class III histone deacetylases
(HDACs). They function by removing acetyl groups from lysines
via consuming NAD (Sinclair and Guarente, 1997). There are
seven human homologs of sirtuins (SIRT1-7), each of which
displays different enzymatic activities and functions (Table 1).
SIRT1, 2, and 3 have strong deacetylase activities, while SIRT4,
5, and 6 have display weak deacetylase activities. SIRT4 and
SIRT6 also display ADP-ribosylase activities, and SIRT5 was
shown to have demalonylase and desuccinylase activities (Shih
and Donmez, 2013). In addition to having unique functions, sir-
tuins are also located in different areas of the cell, including the
nucleus (SIRT1, 6 and 7), cytoplasm (SIRT2), and mitochondria
(SIRT3-5) (Table 1). SIRT1, however, was also reported to shuttle
between cytoplasm and nucleus (Imai and Guarente, 2010).
Numerous target proteins and enzymes have been identified
for sirtuins located in the nucleus, cytoplasm, or mitochondria
(Haigis and Sinclair, 2010). It is established that NAD-dependent
post-translational modification of these targets by sirtuins leads
to the regulation of important biological processes in differ-
ent subcellular compartments and also the effects on age-related
disorders (Donmez and Guarente, 2010).
ALZHEIMER’S DISEASE
AD is the most common neurodegenerative condition and the
most common form of dementia in the elderly. Unfortunately,
there is no cure for this disease. In 2006, there were 26.6 mil-
lion people who suffered from AD worldwide, and the dis-
ease is predicted to affect 1 in 85 people globally by 2050
(Brookmeyer et al., 2007). Patients with AD suffer from neuro-
logical dysfunction resulting in memory loss, as well as cognitive
and functional decline. AD is identified neuropathologically in
mouse models and postmortem patient brains by the pres-
ence of amyloid plaques and neurofibrillary tangles. In addi-
tion, dominant mutations were found in the Amyloid Precursor
Protein (APP) gene and in the presenilin 1 and 2 genes (PSEN1
and PSEN2), which encode for components of gamma-secretase
(Hardy and Selkoe, 2002). APP is cleaved by beta-secretase and
gamma-secretase sequentially to generate Abeta 1-40 and Abeta
1-42 amyloid peptides, which accumulate to form the amy-
loid plaques that are characteristic of AD (Tanzi and Bertram,
2005).
Neurofibrillary tangles are aggregates made up of hyperphos-
phorylated microtubule-associated protein tau. The tau proteins
are the product of alternative splicing from a single gene that
is designated as MAPT (microtubule-associated protein tau) in
humans (Weingarten et al., 1975). All of the six tau isoforms are
present in a hyperphosphorylated state as filaments in the AD
brain. These tau aggregates were also reported to be present in
other neurodegenerative disorders (Alonso et al., 2001).
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Table 1 | Activity and localization of mammalian sirtuins and their effects on AD.
Enzymatic activity Sub-cellular localization Effects on AD Targets related to AD
SIRT1 Deacetylase Nuclear, cytoplasmic Neuroprotective (Chen et al., 2005;
Qin et al., 2006b; Kim et al., 2007;
Julien et al., 2009; Donmez et al.,
2010; Min et al., 2010)
RARb, Tau, PGC1a, LXR,
NFkB
SIRT2 Deacetylase Cytoplasmic, nuclear Genetic association (Polito et al., 2012) Unknown
SIRT3 Deacetylase Mitochondrial Genetic association (Weir et al., 2012) Unknown
SIRT4 Deacetylase
ADP-ribosyltransferase
Mitochondrial Unknown Unknown
SIRT5 Deacetylase
Demalonylase
Desuccinylase
Mitochondrial Unknown Unknown
SIRT6 ADP-ribosyltransferase
Deacetylase
Nuclear Unknown Unknown
SIRT7 Deacetylase Nucleolar Unknown Unknown
ROLE OF SIRT1 IN AD
INITIAL STUDIES
SIRT1 is the only sirtuin that has been extensively studied in
AD. Previous studies showed that the adaptive responses to calo-
rie restriction (CR) are mediated by SIRT1 (Imai and Guarente,
2010). SIRT1-deficient mice were reported not to be able to
adapt to CR normally (Boily et al., 2008). On the other hand,
the phenotypes of SIRT1-overexpressing transgenic mice mimic
the physiological changes observed in CR (Bordone et al., 2007).
These studies established the connection between CR and SIRT1.
The effect of CR on AD was first observed in studies where the
Abeta plaques were reduced in the brains of AD mice that are
calorie-restricted (Patel et al., 2005). Additionally, the cortex of
calorie-restricted squirrel monkeys displayed a reduction in Abeta
plaques, which was inversely correlated with SIRT1 levels (Qin
et al., 2006a).
In a following study, activation of SIRT1 was also shown to be
the mechanism underlying prevention of amyloid neuropathol-
ogy by CR in mouse (Qin et al., 2006b). The authors showed that
exogenous human SIRT1 resulted in reduced serine/threonine
Rho kinase ROCK1 expression and elevated alpha-secretase activ-
ity in vivo. ROCK1 inhibits non-amyloidogenic alpha-secretase
processing of APP (Qin et al., 2006b). These results demonstrated
SIRT1 as an underlyingmechanism through which CR rescues the
AD phenotype in vivo.
STUDIES WITH CELL CULTURE MODELS
SIRT1 was found to be protective against stress in a study con-
ducted with cultured neuronal cells (Qin et al., 2006b). In this
study, SIRT1 expression was found to promote alpha-secretase
activity and attenuates Abeta peptides in primary Tg2576 neu-
ron cultures and CHO-APPswe cells. In another study, SIRT1
was also shown to protect against microglia-dependent amyloid-
beta toxicity in cells through inhibiting inflammatory NF-kappaB
signaling (Chen et al., 2005). In addition to these, N2A cells stably
overexpressing APPswe/PSEN1dE9 transgenes transfected with
SIRT1 displayed reduced Abeta peptides and increased ADAM10
protein levels (Donmez et al., 2010).
Cell culture studies have also helped to discover the effect of
SIRT1 in the tau model and inducible p25 models of AD. In a
recent study, SIRT1 was found to deacetylate tau in HEK293T
cells and primary cortical neurons during maturation in culture
(Min et al., 2010). An earlier study showed that treatment of
primary cortical neurons with low concentrations of ionomycin
and H2O2 induces rapid upregulation of SIRT1 associated with
generation of p25 (Kim et al., 2007). The authors showed that,
in cell-based models for AD/tauopathies and amyotrophic lat-
eral sclerosis (ALS), SIRT1 and resveratrol, a SIRT1-activating
molecule (STAC), promote neuronal survival (Kim et al., 2007).
STUDIES WITH GENETIC MOUSE MODELS
One of the first studies that showed SIRT1 protects against AD
and ALS used mouse models and primary neurons challenged
with neurotoxic insults (Kim et al., 2007). The authors showed
that resveratrol reduced neurodegeneration in the hippocam-
pus, prevented learning impairment, and decreased the acetyla-
tion of the known SIRT1 substrates PGC-1alpha and p53 in an
inducible p25 transgenic mouse, a model of AD and tauopathies
(Kim et al., 2007). In addition, increased levels of SIRT1 in
primary neurons were shown to confer protection against neu-
rotoxicity induced by a mutant form of superoxide dismutase 1
(SOD1G37R), which has been linked to human ALS (Kim et al.,
2007).
Other studies showed that SIRT1 targets both Abeta and
tau in vivo. By crossing a SIRT1-overexpressing mouse or
a SIRT1 brain-specific knockout mouse with the APPswe,
PSEN1dE9 mouse model, SIRT1 expression could be elevated
or deleted in the mouse brain, respectively (Donmez et al.,
Frontiers in Aging Neuroscience www.frontiersin.org April 2013 | Volume 5 | Article 16 | 2
Lalla and Donmez SIRT1 in Alzheimer’s disease
2010). The authors observed that overexpression of SIRT1
reduces Abeta plaques in the mouse brain, while deletion
of SIRT1 exacerbates it. As an underlying mechanism, SIRT1
was shown to deacetylate retinoic acid receptor (RAR)-beta
and activates ADAM10 (alpha-secretase) transcription, which
increases ADAM10 levels in neurons and leads to upreg-
ulated APP processing by alpha-secretase (Donmez et al.,
2010).
In addition to reducing Abeta formation, SIRT1 also inhibits
the tau-related AD phenotype. In one study, SIRT1 reduction
was found to parallel tau accumulation (Min et al., 2010). SIRT1
decreases tau accumulation by deacetylating the acetylated tau
and consequently reducing its level. Conversely, SIRT1 inhibition
leads to the opposite effect, increasing levels of tau, and exacer-
bating the accumulation of pathogenic forms of phosphorylated
tau (Min et al., 2010).
One study used triple-transgenic mouse model of AD, which
is known to accumulate amyloid beta and tau (Julien et al.,
2009). Cortical SIRT1 RNA and protein levels were analyzed in
this mouse model and found to remain unchanged (Julien et al.,
2009).
PATIENT-RELATED STUDIES
Having identified the potential protective role of SIRT1 in cell
culture and genetic mouse models, it is also crucial to investi-
gate the association of SIRT1 with the disease in AD patients.
A recent study compared the mRNA and protein expression lev-
els of SIRT1 in the brains of AD patients and controls using
Western immunoblots and in situ hybridization (Julien et al.,
2009). A significant reduction in RNA and protein expression lev-
els of SIRT1 was reported in the parietal cortex of AD patients.
This reduction was not observed in the cerebellum. The authors
conducted further analyses with a second cohort of 36 subjects
demonstrating that cortical SIRT1 was decreased in individu-
als with AD but not with mild cognitive impairment. SIRT1
mRNA and protein levels were negatively correlated with the
duration of symptoms and the accumulation of tau, but were
weakly correlated with the amyloid-beta 42. The authors con-
cluded that the results of the study indicate that the loss of
SIRT1 is closely associated with the accumulation of amyloid-
beta and tau in the cerebral cortex of AD patients (Julien et al.,
2009).
ROLE OF OTHER SIRTUINS IN AD
Not much is known about the role of SIRT3 in AD. One recent
study showed that pharmacological augmentation of mitochon-
drial ROS increases Sirt3 expression in primary hippocampal
culture (Weir et al., 2012). Furthermore, SIRT3 mRNA is upreg-
ulated in a specific spatio-temporal manner in a PDAPP mouse
model of AD, which overexpresses human APP carrying the
V717F mutation and forms Abeta plaques in mouse brain. In this
study, Sirt3 mRNA expression is significantly increased in samples
of the AD temporal cortex compared to matched controls (Weir
et al., 2012).
SIRT2 has also been found to be associated with AD, as demon-
strated by a genetic case-control study (Polito et al., 2012). In
this study, three single nucleotide polymorphisms (SNPs) were
analysed in a number of AD patients and non-demented control
subjects. An association between SIRT2 rs10410544 T allele and
AD was found in the APOE ε4-negative Caucasian population,
necessitating further investigation (Polito et al., 2012). In the
same study, authors also identified three SNPs for the SIRT3 gene.
CONCLUSIONS
Although, SIRT2 and SIRT3 seem to play a role in AD based
on recent research, SIRT1 is the most extensively studied sir-
tuin in AD. Interestingly, overexpression of SIRT1 was found
to be protective in most of the studies conducted. This might
lead to the design of SIRT1 activators that are able to cross
the blood brain barrier to treat AD. Obviously, SIRT1 has
numerous targets, which is a concern since activating various
targets might not be beneficial for a specific disease. Overall,
studies that use animal and cell culture models show that
SIRT1 plays a neuroprotective role in the brain, a finding that
encourages the design of therapeutics for AD based on SIRT1
activation.
Resveratrol is a natural polypenolic compound that is known
as an activator of SIRT1. However, the association between
SIRT1 and the mechanisms and the biological effects of resver-
atrol is currently debated. Three STACs, SRT1460, SRT1720,
and SRT2183, which are structurally unrelated to, and 1000-
fold more potent than resveratrol, have also been identified as
a result of high throughput screens. When these activators were
implemented in rodent animal studies, including high-fat-diet-
induced obese mice, ob/ob mice, and Zucker fa/fa rats, they
were able to normalize glucose homeostasis (Milne et al., 2007).
A very recent study showed that specific hydrophobic motifs
found in SIRT1 substrates such as PGC-1α and FOXO3a facil-
itate SIRT1 activation by STACs (Hubbard et al., 2013). The
authors also demonstrated that a single amino acid in SIRT1,
Glu(230), located in a structured N-terminal domain, is critical
for activation by all previously reported STAC scaffolds and a new
class of chemically distinct activators. It was concluded therefore,
that SIRT1 can be directly activated through an allosteric mech-
anism common to chemically diverse STACs (Hubbard et al.,
2013).
Nicotinamide (NAM) inhibits the catalytic activity of sirtuins
by binding to a conserved region in the catalytic site (Avalos et al.,
2005). The first sirtuin inhibitor, sirtinol was identified by pheno-
typic screening in yeast (Grozinger et al., 2001) and was shown
to act as an anticancer molecule in various models, inhibiting
Ras-MAPK pathway (Ota et al., 2006).
In future studies, it would be interesting to see whether or
not other sirtuins have an effect on the AD phenotype or dis-
ease pathology. Except for SIRT1, none of the sirtuins have been
analysed extensively in AD. Studying the other sirtuins will also
unravel their novel functions in themammalian brain. Identifying
these functions of sirtuins and their relations to AD will give rise
to therapeutic avenues where new drugs can be developed in an
effort to find a cure for the disease.
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